Fiche centre
Universitatsmedizin Gottingen
Göttingen — Germany
Essais liés8clinical trials
VilleGöttingenlocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06440993
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Left atrial appendage Occlusion | Accident vasculaire cérébral | Non applicable | NCT05976685 | ELAPSE — Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy | RECRUITING |
| Implant of investigational device system | Insuffisance cardiaque | Non applicable | NCT01385176 | Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) | ACTIVE_NOT_RECRUITING |
| Denosumab (reduced dosing) | Cancer | Phase 3 | NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | TERMINATED |
| Gemcitabine | Cancer | Phase 2 | NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma | RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Efgartigimod IV | Myasthénie | À vérifier | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | RECRUITING |
| zeleciment basivarsen (DYNE-101) | Myopathies | Phase 3 | NCT07486934 | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 2 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | RECRUITING |